Analysts are estimating that Biogen will report an earnings per share (EPS) of $3.89. The announcement from Biogen is eagerly ...

Biogen Idec and Swedish Orphan Biovitrum (Sobi) are partners in the development and commercialization of ELOCTATE in hemophilia A and ALPROLIX in hemophilia B. Biogen Idec leads development, has ...

Readers discuss a column by David Brooks. Also: Tears for America; the border reform bill; FAFSA delays; an Alzheimer’s drug; protests in Israel. The pharmaceutical company will give up its ownership ...

What: Shares of Biogen Idec, a global biopharmaceutical company with a primary focus on developing therapies to treat multiple sclerosis, rallied 15% in January, based on data from S&P Capital IQ, ...

SEOUL, Korea & WESTON, Mass.--(BUSINESS WIRE)-- Samsung and Biogen Idec (NASDAQ: BIIB) today announced that they have entered into an agreement to invest $300 million to establish a joint venture to ...

Former Biogen Idec executive Mark Matthews has been appointed to a top sales and marketing post of drug development company Pozen as the company prepares for an expected late 2013 launch of its lead ...

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. Founded in 1978, ...

Idec Pharmaceuticals Corp. and Biogen Inc. announced yesterday that they would merge in a $6.8 billion deal that will create a powerhouse in the biotechnology industry, with the new company earning ...

The search is on for a new head. Mullen rose through the ranks at Biogen after coming on as director of facilities and engineering in 1989. He became head of Biogen in 2000, and kept that post when ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret. By Walt Bogdanich and Carson Kessler The drug, Kisunla, made by ...

Great biotech companies tend to dominate at least one indication. In Biogen's case, that indication is multiple sclerosis. Biogen's Avonex and Tysabri are long-standing blockbuster treatments for ...

This year has turned against biotech investors, as the long-awaited correction came on hard in March and April. While conditions seem to have stabilized for the time being, Biogen Idec remains an ...